Douglas Fleming, MD is the Lead for Medical Safety Assessment for Marketed Products at Bristol-Myers Squibb in Princeton, New Jersey. He did his undergraduate and medical studies at Yale University, and his residency in Internal Medicine at Harvard’s Mount Auburn Hospital in Cambridge, MA. He did a fellowship in public health and epidemiology (the Epidemic Intelligence Service) at the U.S. Centers for Disease Control in Atlanta, in the HIV/STD Division. He spent 15 years in Public health, working as a faculty member of Robert Wood Johnson Medical School at a neighborhood health center among refugees, working on CDC projects as an epidemiologist, and as the Associate Director of Science for Global AIDS Program’s field station in Botswana in southern Africa. He began working for Bristol-Myers Squibb in 2007, first in Clinical and later in Pharmacovigilance. He leads medical assessment for BMS’ Global Pharmacovigilance and Epidemiology for marketed products in cardiovascular, immunology, and virology.